Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).
about
Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategiesResistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase geneRole of Akt signaling in resistance to DNA-targeted therapyNuclear factor-κB-dependent epithelial to mesenchymal transition induced by HIF-1α activation in pancreatic cancer cells under hypoxic conditionsCombination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expressionPotent Sensitisation of Cancer Cells to Anticancer Drugs by a Quadruple Mutant of the Human Deoxycytidine KinaseA phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.Antimetabolites and cancer: emerging data with a focus on antifolates.Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.The increasing role of pharmacogenetics in the treatment of gastrointestinal cancers.Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer.Conjugation of squalene to gemcitabine as unique approach exploiting endogenous lipoproteins for drug delivery.Mechanism of inactivation of human ribonucleotide reductase with p53R2 by gemcitabine 5'-diphosphateBoswellic acid suppresses growth and metastasis of human pancreatic tumors in an orthotopic nude mouse model through modulation of multiple targets.RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy.Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.PharmGKB summary: gemcitabine pathwayDifferential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoproteinAntiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles.Clinical pharmacology and pharmacogenetics of gemcitabine.Overcoming drug resistance in pancreatic cancer.The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1.Novel strategy with gemcitabine for advanced pancreatic cancer.Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cellsPharmacogenomics: a reality or still a promise?Chemoresistance is associated with increased cytoprotective autophagy and diminished apoptosis in bladder cancer cells treated with the BH3 mimetic (-)-Gossypol (AT-101)Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1.Evaluation of a UCMK/dCK fusion enzyme for gemcitabine-mediated cytotoxicity.APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cellsRegulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities.Antimetabolite Treatment for Pancreatic Cancer.Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.Enhanced subunit interactions with gemcitabine-5'-diphosphate inhibit ribonucleotide reductases.MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine.Recent progress in the discovery and development of cyclin-dependent kinase inhibitors.The Cytidine Analog Fluorocyclopentenylcytosine (RX-3117) Is Activated by Uridine-Cytidine Kinase 2.Knockdown of POLA2 increases gemcitabine resistance in lung cancer cells.Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option.Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine.
P2860
Q24645225-C6BE4F6C-289D-4177-A588-15E88606CB8EQ24794747-2444C94B-41D5-42B4-A235-948C85AAE6FAQ28066950-D5C47F7C-8967-4857-A612-3B23C505933AQ28476694-8E619ABF-E285-4D53-A406-FE3C13EB50D5Q28485457-86E3801F-76B2-45ED-881F-259C2C8887DFQ28550404-CDCF7638-DB83-4ADF-95C4-399496C6ABA3Q33402598-D0185C60-86A1-49C5-8045-970AD2D40920Q33530405-516C030A-C8A0-498E-8078-A3623D1FD9CAQ33575608-49EB6452-DD57-41DF-A613-3C3BDC25E260Q33591937-0690F3EB-D4BA-42B5-AF82-71F03668A93CQ33719099-DEB9D26F-3CD6-4904-9D31-9EB05AF87606Q33766617-78E26FAC-2035-4777-9107-3DDA581248F8Q34048376-0DBA122F-54FB-4B06-B3B4-A742C3C705D6Q34069637-791D16EE-3169-42D1-8EBE-86FBAF6BE2A4Q34165809-13B255B1-55C2-4A8E-A412-A478AB53967EQ34254837-CE51A85B-0592-404D-A9DB-3AE125F463E4Q34435450-50B72703-940A-43B9-99BF-B96F9410DD4EQ34555685-787B6970-E7D3-4538-9EEB-212F5B20A7C1Q34792522-AFE8CDF1-8A49-4DA2-BA46-B0CBC3B16AD5Q34819537-65294662-58EF-4839-85BB-1F0EB16F5B9DQ34985979-89CAE6CC-CDA4-423B-8008-E2608D33A42AQ35036615-CF141FAC-F578-4659-9559-737C737EF658Q35194201-C0B96E67-2180-40EE-8F75-580CDD6F1441Q35432223-DCDD859F-60C4-4229-BB6A-5422B1ED2154Q35486194-0344633B-3A70-453B-832D-D1C472479CA0Q35565186-68E61905-76DE-4623-93FB-F3A8BB477AD5Q35605849-4954A8EE-7DD2-47ED-9374-6FD4D3120101Q35610203-389BB6CF-3C7B-48DC-85B4-91BFA62C246CQ35613655-0D656D87-E5DC-4D97-9D2E-396E15926DFDQ35667409-A65D592D-22B0-4B59-A40E-E1562DFBE708Q35742631-208E3AEF-7830-44F4-A01F-9CF8D80A0A30Q35826334-65BEEE69-058C-4A5D-9707-EB243EDFBAEBQ35909171-3EB8ADC7-9E64-4243-B8A5-6FC18FA8DF11Q35971682-85A42F0C-508F-44EC-8959-B581A3B6611EQ35987380-BF094D2A-C079-408F-BB7E-F6058B4F1A11Q36120794-685A8F6F-1387-4914-B32D-0076EEAA36FAQ36128648-EE6DB47C-4234-4CC5-8647-96A4A5ABF127Q36268729-9997A460-E3BC-45C2-9209-7A66B521D78AQ36286371-9C3B41FE-A410-4D3A-99FD-A6A9794F501AQ36342657-259D17E1-3A14-4882-A904-BB7A2F4C7368
P2860
Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).
@ast
Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).
@en
Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).
@nl
type
label
Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).
@ast
Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).
@en
Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).
@nl
prefLabel
Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).
@ast
Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).
@en
Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).
@nl
P2093
P1476
Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).
@en
P2093
Andries M Bergman
Godefridus J Peters
Herbert M Pinedo
P356
10.1016/S1368-7646(02)00002-X
P577
2002-02-01T00:00:00Z